Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRB 796 BS in endotoxin-induced inflammation
NCT02211170Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2000
- Primary completion
- Apr 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of doramapimod in Crohn's disease, psoriasis and rheumatoid arthritis (RA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Reduction of tumour necrosis factor alpha (TNFα) concentration up to 2 days. Started Feb 2000; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseasepsoriasisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02211170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211170.